https://www.selleckchem.com/pr....oducts/crenolanib-cp
The cost of metastatic triple-negative breast cancer (mTNBC) continues to rise; before the use of immune checkpoint inhibitors in mTNBC, cumulative costs of treatment ranged from $51,070 for patients not treated with chemotherapy, up to $143,150 for patients who received three or more regimens. For those with programmed death ligand 1 (PD-L1)-positive mTNBC, expanding treatments continue to be approved for combination first-line therapy. Both combination atezolizumab with nab-paclitaxel and pembrolizumab with chemotherapy h
Aimer
Commentaire
Partagez
